Needham & Company
View Older Stories
-
CONMED (CNMD) PT Lowered to $106 at Needham
-
CONMED (CNMD) PT Lowered to $107 at Needham
-
CONMED (CNMD) PT Lowered to $150 at Needham & Company
-
CONMED (CNMD) PT Raised to $158 at Needham & Company
-
UPDATE: Needham & Company Upgrades CONMED (CNMD) to Buy
-
Needham & Company Downgrades CONMED (CNMD) to Hold
-
CONMED (CNMD) PT Raised to $115 at Needham & Company
-
CONMED (CNMD) PT Raised to $111 at Needham & Company
-
CONMED (CNMD) PT Raised to $95 at Needham & Company
-
Conmed (CNMD) PT Rises To $94 On Surgical Smoke Opportunity - Needham
-
CONMED (CNMD) PT Raised to $87 at Needham & Company
-
CONMED (CNMD) PT Lowered to $79 at Needham & Company
-
CONMED (CNMD) PT Raised to $88 at Needham & Company
-
CONMED (CNMD) PT Raised to $83 at Needham & Company
-
CONMED (CNMD) PT Raised to $73 at Needham & Company
-
CONMED (CNMD) PT Raised to $71 at Needham & Company
-
CONMED (CNMD) PT Raised to $58 at Needham & Company Following 3Q Report
-
Conmed (CNMD): Raising PT Ahead Of Product Line Expansion - Needham
-
Needham & Company Raises Price Target on Conmed (CNMD) to $53 After Hosting Investor Meeting
-
ResMed (RMD), St. Jude (STJ), Cepheid (CPHD) Among Med Tech Companies with Most EU Exposure - Needham & Company
-
CONMED Corporation (CNMD) PT Increased to $49 - Needham & Company
-
Needham & Company Raises Price Target to $60 Following Conmed's (CNMD) 2Q Miss
-
CONMED Corporation to Present at the 14th Annual Needham Healthcare Conference
-
CONMED (CNMD) PT Raised to $52 at Needham & Company on Faster Revenue Growth
-
Needham & Company Comments on Sector Implications Amid Medtronic (MDT)/Covidien (COV) Megadeal
-
CONMED (CNMD) Worth up to $59/Share in Takeover - Needham & Company
-
CONMED (CNMD) Target, Estimates Lifted at Needham & Company
-
CONMED (CNMD) Target Lifted to $48 at Needham & Company
-
Needham & Company Starts CONMED (CNMD) at Buy
-
Needham & Company Maintains a 'Buy' on CONMED (CNMD); Adjusting Numbers on Mixed Qtr
-
Needham & Company Reiterates a 'Buy' on CONMED (CNMD); Setting Positive Tone for 2012
-
Needham & Company Reiterates a 'Buy' on CONMED (CNMD); Net Positive Quarter with Mixed Results at Segment Level
-
Needham & Company Reiterates a 'Buy' on CONMED (CNMD); Beats Top & Bottom Lines as U.S. Growth & Capital Equipment Sales Pick Up

